Ernest Mario Net Worth

The estimated Net Worth of Ernest Mario is at least $104 Milion dollars as of 31 March 2022. Ernest Mario owns over 1,860,000 units of Soleno Therapeutics Inc stock worth over $45,179,400 and over the last 17 years he sold SLNO stock worth over $58,963,774. In addition, he makes $88,443 as Independent Chairman of the Board at Soleno Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ernest Mario SLNO stock SEC Form 4 insiders trading

Ernest has made over 197 trades of the Soleno Therapeutics Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 1,860,000 units of SLNO stock worth $90,358,800 on 31 March 2022.

The largest trade he's ever made was buying 1,860,000 units of Soleno Therapeutics Inc stock on 31 March 2022 worth over $90,358,800. On average, Ernest trades about 17,580 units every 16 days since 2007. As of 31 March 2022 he still owns at least 930,000 units of Soleno Therapeutics Inc stock.

You can see the complete history of Ernest Mario stock trades at the bottom of the page.

Ernest Mario biography

Dr. Ernest B. Mario Ph.D. serves as Independent Chairman of the Board of the Company.D. serves as Independent Chairman of the Board of the Company.D. serves as Independent Chairman of the Board of the Company. Dr. Mario joined our Board of Directors in August 2007 and served as Chairman and Chief Executive Officer until February 2014 when he was named Chairman. From April 2003 to August 2007, Dr. Mario served as Chief Executive Officer and Chairman of Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company that was acquired by GSK for approximately $1.6 billion in 2007. Dr. Mario served as Chief Executive Officer and Chairman of ALZA Corporation, a research-based pharmaceutical company, from November 1997 to December 2001, when ALZA was acquired by Johnson & Johnson for approximately $12 billion. Previously he served as Chief Executive Officer and Co-Chairman of ALZA from August 1993 to November 1997. From January 1992 until March 1993, Dr. Mario served as Deputy Chairman of Glaxo Holdings plc., a pharmaceutical company, and as Chief Executive from May 1989 to March 1993. Dr. Mario has current and past service on a number of corporate boards including Boston Scientific Corporation, Celgene Inc. (current), Chimerix, Inc. (current), Kindred Biosciences Inc., Tonix Pharmaceuticals Holding Corp. (current) and XenoPort Inc. Dr. Mario earned his M.S. and Ph.D. in physical sciences at the University of Rhode Island and a B.S. in pharmacy at Rutgers. He holds honorary doctorates from the University of Rhode Island and Rutgers University. In 2007, he was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor.

What is the salary of Ernest Mario?

As the Independent Chairman of the Board of Soleno Therapeutics Inc, the total compensation of Ernest Mario at Soleno Therapeutics Inc is $88,443. There are 5 executives at Soleno Therapeutics Inc getting paid more, with Anish Bhatnagar having the highest compensation of $822,089.

How old is Ernest Mario?

Ernest Mario is 81, he's been the Independent Chairman of the Board of Soleno Therapeutics Inc since 2014. There are no older and 10 younger executives at Soleno Therapeutics Inc.

What's Ernest Mario's mailing address?

Ernest's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94062.

Insiders trading at Soleno Therapeutics Inc

Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler oraz Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.

What does Soleno Therapeutics Inc do?

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.

Complete history of Ernest Mario stock trades at Chimerix Inc, Kindred Biosciences Inc, Soleno Therapeutics Inc, Tonix Pharmaceuticals Corp, VIVUS, Boston Scientific oraz Eyenovia Inc

Soleno Therapeutics Inc executives and stock owners

Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anish Bhatnagar,
  President, Chief Executive Officer, Director
• Dr. Anish Bhatnagar,
  Pres, CEO, COO & Director
• Patricia Hirano,
  Vice President - Regulatory Affairs
• Kristen Yen,
  Vice President - Clinical Operations
• James H. MacKaness,
  Chief Financial Officer
• Ernest Mario,
  Independent Chairman of the Board
• William Harris,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Birgitte Volck,
  Independent Director
• Andrew Sinclair,
  Independent Director
• Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
  Sr. VP of Drug Devel.
• Anthony Wondka,
  Sr. VP & GM
• Dawn Carter Bir,
  
• Jack W Schuler,
  
• Larry N Feinberg,
  10% owner
• Opportunity, Llc Vivo Oppor...,
  
• Jonathan Wolter,
  Chief Financial Officer
• Stephen Kirnon,
  Director
• Mahendra Shah,
  Director
• Rajen Dalal,
  Director
• Edgar Engleman,
  Director
• Ventures V, Llc Vivo,
  10% owner
• Steinar J Engelsen,
  Director
• James Walter Glasheen,
  Director
• Stuart J Collinson,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Raymond W. Urbanski,
  CHIEF DEVELOPMENT OFFICER
• Management Vii Llctechnolog...,
  
• Mangement Llcbioasia Invest...,
  
• Larry Noracle Partners Lp F...,
  
• Llp Abingworth,
  10% owner
• Ventures V, Llc Vivo Ventur...,
  
• Group Inc.Carlyle Holdings ...,
  
• Meredith Manning,
  Chief Commercial Officer
• Michael F. Huang,
  Sr. VP of Clinical Development
• Matthew Pauls,
  
• Group Inc.Carlyle Holdings ...,
  
• Advisors Llcperceptive Life...,
  
• James H Mackaness,
  CHIEF FINANCIAL OFFICER